B Group Inc. Takes $399,000 Position in BioNTech SE (NASDAQ:BNTX)

B Group Inc. acquired a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,500 shares of the company's stock, valued at approximately $399,000. BioNTech accounts for approximately 0.2% of B Group Inc.'s portfolio, making the stock its 16th biggest holding.

Other institutional investors and hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC increased its holdings in BioNTech by 412.3% in the fourth quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after buying an additional 33,375 shares during the last quarter. Mirabaud & Cie SA acquired a new position in shares of BioNTech during the 4th quarter worth $684,000. Bank of New York Mellon Corp raised its holdings in shares of BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after purchasing an additional 150 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of BioNTech in the 4th quarter valued at $1,118,000. Finally, Retireful LLC acquired a new stake in shares of BioNTech in the 4th quarter valued at $260,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded down $18.52 during trading hours on Friday, reaching $102.02. The stock had a trading volume of 6,438,309 shares, compared to its average volume of 897,110. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The business's fifty day moving average is $101.72 and its two-hundred day moving average is $110.64. The company has a market cap of $24.48 billion, a price-to-earnings ratio of -48.58 and a beta of 1.07.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period last year, the firm earned $1.90 EPS. As a group, research analysts expect that BioNTech SE will post -3.88 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BNTX. Morgan Stanley cut their target price on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a report on Tuesday, March 11th. HC Wainwright cut their price objective on BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Truist Financial started coverage on BioNTech in a research report on Friday, January 10th. They set a "buy" rating and a $172.00 target price for the company. BMO Capital Markets increased their price target on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $143.44.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.